The Benelux region - comprising the Belgium, Netherlands and Luxembourg - has established itself as Europe’s premier "Conjugation Hub," home to some of the world’s most sophisticated ADC engineering technologies. This ecosystem is uniquely defined by its leadership in site-specific bioconjugation (the art of precisely attaching a drug to an antibody) and the pioneering of Nanobody-based delivery, which allows for deeper tumor penetration than traditional antibody formats.

Centered around the high-density biotech clusters in Leiden, Nijmegen, and Ghent, the region thrives on a "spin-off" culture where world-class academic institutions like the VIB and the Netherlands Cancer Institute (NKI) continuously fuel new ventures. While home-grown players like Synaffix act as the "intel inside" for dozens of global pharma pipelines, international giants such as Johnson & Johnson and Sanofi have chosen the Benelux as their primary European centers of excellence for biologics manufacturing and next-generation targeted research.